Objective?To analyze the clinical efficacy of aspirin and clopidogrel in the clinical treatment of patients with cerebral infarction. Methods?A total of 80 patients with cerebral infarction admitted to Huimin People's Hospital from June 2019 to June 2021 were selected as the study subjects, and were divided into observation group (treated with aspirin combined with clopidogrel) and control group (treated with aspirin) according to random number table method. The clinical efficacy, national institutes of health neurological deficit score (NIHSS), daily living ability score (ADL), levels of blood lipids, inflammatory factors, coagulation function indexes and incidence of adverse reactions were compared between 2 groups. Results?The clinical effective rate of control group was lower than observation group (P ＜ 0.05); After treatment, NIHSS score was decreased and ADL score was increased in both groups, and NIHSS score in control group was higher than that in observation group, while ADL score was higher than that in control group (P ＜ 0.05); After treatment, the levels of various lipid indexes, inflammatory factors and fibrinogen (FIB) in both groups were decreased, and the activated partial thrombin time (APTT) and prothrombin time (PT) were increased, and the levels of lipid indexes, inflammatory factors and FIB in control group were higher than those in observation group, APTT and PT were shorter than those of obserration group (P ＜ 0.05). There was no significant difference in the rate of adverse reactions between both groups (P ＞ 0.05).Conclusion?In the clinical treatment of patients with cerebral infarction, the treatment of aspirin and clopidogrel can improve the curative effect, neurological function and living ability of patients, and can effectively improve the patient's lipid index, inflammatory response and coagulation function, and the combined treatment is high safety, worthy of clinical promotion and application.